ArticleDigestive diseases and sciences2026
The SILVER Platter for Patients with Inflammatory Bowel Disease (IBD): An IBD Pharmacy Technician-Led Subcutaneous Biologic Home Delivery Service Is Associated with Sustained Improvement in Adherence and Active Health Management.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSubcutaneous medications are associated with lower adherence, risking adverse disease outcomes. This project aimed to evaluate the effect of a pharmacy technician-led subcutaneous biologic home delivery (SILVER) service on medication adherence, health literacy, and disease outcomes in patients with inflammatory bowel disease (IBD).
methodsPatients treated with a subcutaneous biologic, residing within 45 min of a tertiary IBD service, were offered home delivery of the biologic. Demographic and clinical data were recorded. Telephone interviews at baseline, 6 months, and 12 months were performed to evaluate change in quality of life via Short Inflammatory Bowel Disease Questionnaire (SIBDQ), medication adherence, health literacy via Health Literacy Questionnaire, and electronic Health Literacy Questionnaire (HLQ & eHLQ) and clinical disease activity.
resultsEighty patients were included. 45 (56.3%) patients were treated with ustekinumab, 23 (28.8%) with adalimumab, 11 (13.8%) with subcutaneous infliximab and 1 (1.2%) with subcutaneous vedolizumab. Significant improvement (p ≤ 0.05) was observed at 6 and 12 months in SIBDQ, adherence, and HLQ/eHLQ (two domains), and fecal calprotectin at 6 months. Of these patients, 43 were treated with the same biologic agent and route for at least 6 months prior to enrollment. In this subgroup, significant improvement (p ≤ 0.05) was measured at 6 and 12 months in SIBDQ, adherence, and HLQ/eHLQ (one domain).
conclusionsA novel pharmacy technician-led subcutaneous biologic home delivery service was associated with improvement in IBD-related quality of life, medication adherence, health literacy, and disease outcomes, sustained to 12 months. Larger studies are warranted to evaluate home delivery of subcutaneous biologics in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.